ClouDr Group Limited (stock code: 9955) announced an expected consolidated net loss ranging between RMB 880.00 million and RMB 980.00 million for the year ended December 31, 2025. This compares to a net loss of RMB 491.40 million in the prior year.

The primary factor cited for the projected increase is the strategic transformation aimed at focusing on core AI capabilities. This shift led to significant impairment losses on certain subsidiaries and a one-off specific provision related to a business under major legal proceedings. Meanwhile, the Group’s strategic divestment from low-margin medical supplies and concentration on an AI-driven P2M business model are expected to improve operating efficiency.

According to the announcement, the net cash inflow from operating activities is forecast to be between RMB 50.00 million and RMB 80.00 million for the reporting period, compared to a net cash outflow of RMB 148.40 million in the previous year. The figures in the announcement have yet to be audited or reviewed by the Group’s independent auditor, and final results are expected to be released by the end of March 2026.